"Finally, may I ask what evidence you are relying on to suggest that even with FDA de novo clearance for Coris, not all types of flexible endoscopes will be covered right away, and, that some indications will require further 510k applications? That would be a huge surprise to me and I've never heard anything to that effect from the company or from any of the analysts that cover Nanosonics, so any clarification you can provide would be appreciated."
That took me by surprise too. I am used to being surprised in following NAN. I notice SELECTOR FUNDS has increased their equity in NAN to nearly 8%.
They are not shorters and take little notice of INDEX membership...............NAN removed from the ASX 200
"Finally, may I ask what evidence you are relying on to suggest...
Add NAN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.30 |
Change
-0.020(0.60%) |
Mkt cap ! $1.001B | |||
| Open | High | Low | Value | Volume |
| $3.31 | $3.31 | $3.21 | $1.190M | 362.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1594 | $3.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.31 | 1243 | 2 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| NAN (ASX) Chart |